Natural Anti-Endothelial Cell Antibodies in Patients Undergoing Coronary Angiography.


Journal

The Israel Medical Association journal : IMAJ
ISSN: 1565-1088
Titre abrégé: Isr Med Assoc J
Pays: Israel
ID NLM: 100930740

Informations de publication

Date de publication:
Oct 2021
Historique:
entrez: 21 10 2021
pubmed: 22 10 2021
medline: 27 10 2021
Statut: ppublish

Résumé

Anti-endothelial cell antibodies (AECA) are a known biomarker of endothelial dysfunction and damage in clinical practice, especially in autoimmune disease. To determine the relation between natural AECA levels and prognosis related to coronary artery disease. Candidates for coronary angiography were prospectively enrolled. AECA levels were determined by ELISA assay. Mortality was evaluated after more than 5 years follow-up. Of a total 857 patients, 445 had high AECA levels (group 1) and 412 had low levels (< 1 OD unit, group 2). Both groups did not differ in age, sex, or presence of diabetes. The median follow up was 2293 days (76 months). Patients with high AECA levels were more likely to have normal coronary arteries on angiography (21.6% vs. 16.9%, P = 0.047) and less likely to have calcified lesions (19.0% vs. 26.6%, P = 0.028) and lower prevalence of abnormal renal functions (71.1 mg/dl vs. 66.5 mg/dl, P = 0.033). Patients with higher AECA levels had lower mortality levels (20.1% vs. 27.6%, P = 0.006). A logistic regression model demonstrated independent association between lower AECA levels and the presence of coronary atherosclerosis based on angiogram. After a median of more than 6 years, higher natural AECA levels were associated with less coronary artery disease and lower mortality rates in patients undergoing coronary angiography.

Sections du résumé

BACKGROUND BACKGROUND
Anti-endothelial cell antibodies (AECA) are a known biomarker of endothelial dysfunction and damage in clinical practice, especially in autoimmune disease.
OBJECTIVES OBJECTIVE
To determine the relation between natural AECA levels and prognosis related to coronary artery disease.
METHODS METHODS
Candidates for coronary angiography were prospectively enrolled. AECA levels were determined by ELISA assay. Mortality was evaluated after more than 5 years follow-up.
RESULTS RESULTS
Of a total 857 patients, 445 had high AECA levels (group 1) and 412 had low levels (< 1 OD unit, group 2). Both groups did not differ in age, sex, or presence of diabetes. The median follow up was 2293 days (76 months). Patients with high AECA levels were more likely to have normal coronary arteries on angiography (21.6% vs. 16.9%, P = 0.047) and less likely to have calcified lesions (19.0% vs. 26.6%, P = 0.028) and lower prevalence of abnormal renal functions (71.1 mg/dl vs. 66.5 mg/dl, P = 0.033). Patients with higher AECA levels had lower mortality levels (20.1% vs. 27.6%, P = 0.006). A logistic regression model demonstrated independent association between lower AECA levels and the presence of coronary atherosclerosis based on angiogram.
CONCLUSIONS CONCLUSIONS
After a median of more than 6 years, higher natural AECA levels were associated with less coronary artery disease and lower mortality rates in patients undergoing coronary angiography.

Identifiants

pubmed: 34672449

Substances chimiques

Autoantibodies 0
Biomarkers 0
anti-endothelial cell antibody 0

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

657-661

Auteurs

Nicholay Teodorovich (N)

Kaplan Heart Center, Kaplan Medical Center, Rehovot, affiliated with Hadassah Medical Organization and Faculty of Medicine, Hebrew University of Jerusalem, Israel.

Michael Jonas (M)

Kaplan Heart Center, Kaplan Medical Center, Rehovot, affiliated with Hadassah Medical Organization and Faculty of Medicine, Hebrew University of Jerusalem, Israel.

Dan Haberman (D)

Kaplan Heart Center, Kaplan Medical Center, Rehovot, affiliated with Hadassah Medical Organization and Faculty of Medicine, Hebrew University of Jerusalem, Israel.

Haitham Abu Khadija (H)

Kaplan Heart Center, Kaplan Medical Center, Rehovot, affiliated with Hadassah Medical Organization and Faculty of Medicine, Hebrew University of Jerusalem, Israel.

Omar Ayyad (O)

Kaplan Heart Center, Kaplan Medical Center, Rehovot, affiliated with Hadassah Medical Organization and Faculty of Medicine, Hebrew University of Jerusalem, Israel.

Gera Gandelman (G)

Kaplan Heart Center, Kaplan Medical Center, Rehovot, affiliated with Hadassah Medical Organization and Faculty of Medicine, Hebrew University of Jerusalem, Israel.

Lion Poles (L)

Kaplan Heart Center, Kaplan Medical Center, Rehovot, affiliated with Hadassah Medical Organization and Faculty of Medicine, Hebrew University of Jerusalem, Israel.

Jacob George (J)

Kaplan Heart Center, Kaplan Medical Center, Rehovot, affiliated with Hadassah Medical Organization and Faculty of Medicine, Hebrew University of Jerusalem, Israel.

Alex Blatt (A)

Kaplan Heart Center, Kaplan Medical Center, Rehovot, affiliated with Hadassah Medical Organization and Faculty of Medicine, Hebrew University of Jerusalem, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH